• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Covance, PathoQuest partner on biosafety assessments

Covance, PathoQuest partner on biosafety assessments

November 6, 2013
CenterWatch Staff

CRO Covance and PathoQuest, in the field of pathogen detection, have announced an exclusive agreement to collaborate to provide Next-Generation Sequencing (NGS)-based biosafety assessments.

This biosafety testing approach, combined with Covance’s regulatory experience, provides a flexible testing solution to all biotherapeutic clients and makes biologic medicines safer.

Since viral contamination poses a significant potential safety risk to patients, regulatory agencies are increasingly focusing on the use of advanced analytical technologies like NGS for detection of viral contaminants. The new NGS-based platform can detect and identify viral contaminants within biologic compounds (such as monoclonal antibodies or vaccines) throughout the entire lifecycle of the product.

“This collaboration will provide Covance clients with a high-quality solution to the critical problem of viral contamination of biologics during development and in released product,” said Raymond Kaiser, Ph.D., global vice president of biopharmaceutical chemistry, manufacturing and control (CMC) solutions for Covance.

“Covance’s global footprint and extensive experience in BioCMC development, together with their established in-house biosafety testing capabilities, offer perfect synergies to help clients access our NGS-based adventitious assay globally. In an evolving regulatory environment, we anticipate that NGS will soon become the standard approach in biosafety assessment. Our technology will help clients meet that standard now and well into the future,” said Luc Boblet, Ph.D., co-founder and CEO of PathoQuest.

The industry is increasingly adopting the technology, with several high-profile instances of viral contamination of commercially released biologic drugs detected by NGS. The NGS solution offered by Covance and PathoQuest overcomes the primary limitation of traditional approaches that identify only a predefined short list of viruses. NGS provides a universal test for identifying any virus in a single, comprehensive analysis that minimizes false negatives.

Covance and PathoQuest will provide clients with a wide range of options for adventitious virus identification. This includes a rapid detection protocol for the critical evaluation of major issues within production processes and a more comprehensive approach for development and characterization of cell banks and biological production systems. For small, emerging and virtual biotech companies, representing a growing and valued segment of Covance’s client base, this solution allows them access to a unique technology early in the development process that will increase the value and safety profile of their molecule.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing